Quadrivalent meningococcal conjugate vaccines
<em>Neisseria meningitidis</em> is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2009
|
| Subjects: |
| _version_ | 1797075064640765952 |
|---|---|
| author | Pace, D Pollard, A Messonier, N |
| author_facet | Pace, D Pollard, A Messonier, N |
| author_sort | Pace, D |
| collection | OXFORD |
| description | <em>Neisseria meningitidis</em> is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. This vaccine and others in development offer the potential to broaden population protection against meningococcal disease. |
| first_indexed | 2024-03-06T23:45:04Z |
| format | Journal article |
| id | oxford-uuid:709e10f4-9bda-49b6-8b29-dc0f74b089c8 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:45:04Z |
| publishDate | 2009 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:709e10f4-9bda-49b6-8b29-dc0f74b089c82022-03-26T19:38:18ZQuadrivalent meningococcal conjugate vaccinesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:709e10f4-9bda-49b6-8b29-dc0f74b089c8VaccinologyMeningitisPaediatricsEnglishOxford University Research Archive - ValetElsevier2009Pace, DPollard, AMessonier, N<em>Neisseria meningitidis</em> is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. This vaccine and others in development offer the potential to broaden population protection against meningococcal disease. |
| spellingShingle | Vaccinology Meningitis Paediatrics Pace, D Pollard, A Messonier, N Quadrivalent meningococcal conjugate vaccines |
| title | Quadrivalent meningococcal conjugate vaccines |
| title_full | Quadrivalent meningococcal conjugate vaccines |
| title_fullStr | Quadrivalent meningococcal conjugate vaccines |
| title_full_unstemmed | Quadrivalent meningococcal conjugate vaccines |
| title_short | Quadrivalent meningococcal conjugate vaccines |
| title_sort | quadrivalent meningococcal conjugate vaccines |
| topic | Vaccinology Meningitis Paediatrics |
| work_keys_str_mv | AT paced quadrivalentmeningococcalconjugatevaccines AT pollarda quadrivalentmeningococcalconjugatevaccines AT messoniern quadrivalentmeningococcalconjugatevaccines |